Showing results (151-160 of 376) with videos related to
Sort By:
Pageof 38
Metabolism: Clinical and Experimental|May 20, 2017
High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patientsJosé M Gallego-Escuredo, Maria Karuna Lamarca, Joan Villarroya, et al.AIDS (London, England)|September 29, 2012
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravirEsteban Martínez, Polyana M D'Albuquerque, Josep M Llibre, et al.AIDS (London, England)|January 27, 2007
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patientsEsteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.The Journal of Infectious Diseases|August 1, 2023
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir AlafenamideSofía Scévola, Jordi Niubó, Pere Domingo, et al.Life Sciences|September 12, 2022
Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytesPere Domingo, Tania Quesada-López, Joan Villarroya, et al.AIDS Research and Human Retroviruses|December 28, 2007
A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeksJean-Michel Molina, Thomas J Podsadecki, Margaret A Johnson, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensificationMarta Massanella, Anna Esteve, Maria J Buzón, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patientsJosé M Gallego-Escuredo, Pere Domingo, Maria del Mar Gutiérrez, et al.The Journal of Antimicrobial Chemotherapy|December 22, 2016
Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individualsEugènia Negredo, Vicente Estrada, Pere Domingo, et al.Enfermedades Infecciosas Y Microbiologia Clinica|August 24, 2015
Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical indexCesar Velasco, Inaki Pérez, Daniel Podzamczer, et al.Pageof 38